JWH-302

JWH-302 is a synthetic cannabinoid from the naphthoylindole family, which acts as a full agonist at both the CB₁ and CB₂ cannabinoid receptors, with a moderate selectivity for CB₂. It was discovered by and named after John W. Huffman, an organic chemist at Clemson University.

Chemistry

JWH-302 is part of the naphthoylindole family of synthetic cannabinoids. It is structurally related to other synthetic cannabinoids such as JWH-018 and JWH-073, but differs in the substitution on the indole ring. JWH-302 has a methoxy group at the 5-position of the indole ring, whereas JWH-018 has a naphthyl group and JWH-073 has a butyl chain.

Pharmacology

JWH-302 acts as a full agonist at both the CB₁ and CB₂ cannabinoid receptors, with a moderate selectivity for CB₂. The CB₁ receptor is primarily located in the brain and mediates the psychoactive effects of cannabinoids, while the CB₂ receptor is primarily found in the immune system and is involved in immune response and inflammation.

Effects

The effects of JWH-302 are similar to those of other synthetic cannabinoids and include euphoria, relaxation, altered perception, and in some cases, hallucinations. However, due to its full agonist activity at the cannabinoid receptors, JWH-302 may have a higher potential for adverse effects and dependence compared to partial agonists like THC, the main active component of cannabis.

Legal Status

The legal status of JWH-302 varies by country and is often subject to change. In many countries, including the United States, it is classified as a controlled substance due to its potential for abuse and dependence.

See Also

• Synthetic cannabinoids
• Cannabinoid receptor
• John W. Huffman